GT Biopharma, Inc. (GTBP) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.85M | 5.59M | 3.38M | 1.51M | 1.93M | 3.76M | 3.6M | 3.91M | 3.09M | 3.17M | 3.12M | 3.62M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.44M | 4.22M | 2.75M | 1.15M | 833K | 1.83M | 2.3M | 2.12M | 2.31M | 1.81M | 1.76M | 1.53M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 413K | 1.38M | 634K | 363K | 1.1M | 1.93M | 1.31M | 1.78M | 777K | 1.36M | 1.36M | 2.1M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.85M | -5.59M | -3.38M | -1.51M | -1.93M | -3.76M | -3.6M | -3.91M | -3.09M | -3.17M | -3.12M | -3.62M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -47.41% | -48.68% | 6.16% | 61.26% | 37.5% | -18.78% | -15.44% | -7.87% | 15.66% | 45.17% | 55.55% | -20.14% |
| EBITDA | -2.85M | -5.59M | -3.38M | -1.51M | -1.93M | -3.77M | -3.41M | -3.71M | 0 | -2.96M | -2.42M | -1.99M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -47.41% | -48.21% | 0.85% | 59.22% | - | -27.45% | -41.18% | -86.34% | 100% | 46.88% | 64.89% | 33.17% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.09M | 0 | 0 | 0 |
| EBIT | -2.85M | -5.59M | -3.38M | -1.51M | -1.93M | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M |
| Net Interest Income | 4K | -110K | 36K | 38K | 32K | 59K | 96K | 105K | 142K | 180K | 216K | 219K |
| Interest Income | 67K | 17K | 36K | 38K | 32K | 59K | 96K | 105K | 142K | 180K | 216K | 220K |
| Interest Expense | 63K | 127K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K |
| Other Income/Expense | 15K | -17.44M | 11.68M | -28.66M | 1.16M | -12K | 193K | 196K | 825K | 206K | 706K | 1.63M |
| Pretax Income | -2.83M | -23.03M | 8.3M | -30.17M | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.83M | -23.03M | 8.3M | -30.17M | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -265.08% | -510.09% | 343.3% | -713.18% | 65.75% | -27.45% | -41.18% | -86.25% | -898.24% | 46.96% | 64.89% | 33.13% |
| Net Income (Continuing) | -2.83M | -23.03M | 8.3M | -30.17M | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.11 | -4.97 | -0.83 | -0.55 | -0.33 | -1.99 | -1.53 | -2.17 | -1.64 | -2.15 | -1.77 | -1.49 |
| EPS Growth % | 66.67% | -149.75% | 45.75% | 74.65% | 79.88% | 7.44% | 13.56% | -45.64% | -680.95% | 54.45% | -129.87% | 47.9% |
| EPS (Basic) | -0.11 | -4.97 | -0.83 | -0.55 | -0.33 | -1.99 | -1.53 | -2.17 | -1.64 | -2.15 | -1.77 | -1.49 |
| Diluted Shares Outstanding | 30.28M | 5.51M | 3.94M | 2.77M | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M |
| Basic Shares Outstanding | 30.28M | 5.51M | 3.94M | 2.77M | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M |
| Dividend Payout Ratio | - | - | 1.02% | - | - | - | - | - | - | - | - | - |